Do you want to read an article? Please log in or register.
No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis
Inflamm Bowel Dis
Shehab M, Hassan A, Alrashed F, Abbas A, Ma C, Narula N, Jairath V, Singh S, Bessissow T
doi: 10.1093/ibd/izae163
Inflammatory Bowel Disease
Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in UC: Analyses of the ELEVATE UC Clinical Programme
J Crohns Colitis
Sands BE, Leung Y, Rubin DT, Gecse KB, Panés J, Goetsch M, Wang W, Woolcott JC, Smith CC, Wosik K, Schreiber S
doi: 10.1093/ecco-jcc/jjae150
Gastrointestinal Cancer
The Impact of Advanced Medical Therapies on Time to Resection and Colorectal Cancer Outcomes in Ulcerative Colitis Patients Undergoing Colectomy
J Crohns Colitis
Visser E, Luberto A, Heuthorst L, Hompes R, Vermeire S, D'Haens GR, Bemelman WA, D'Hoore A, Bislenghi G, Buskens CJ
doi: 10.1093/ecco-jcc/jjaf015
Inflammatory Bowel Disease
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis
Adv Ther
Dignass A, Ainsworth C, Hartz S, Dunnewind N, Redondo I, Sapin C, Kroep S, Halfpenny N, Arcà E, Hoque S
doi: 10.1007/s12325-024-03003-8
Inflammatory Bowel Disease
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis
J Crohns Colitis
D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S
doi: 10.1093/ecco-jcc/jjaf080
Inflammatory Bowel Disease
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflamm Bowel Dis
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A
doi: 10.1093/ibd/izae253
Inflammatory Bowel Disease
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Lancet Gastroenterol Hepatol
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S
doi: 10.1016/S2468-1253(25)00017-2
Inflammatory Bowel Disease
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Inflamm Bowel Dis
Sands BE, Dubinsky MC, Kotze PG, Vermeire S, Panaccione R, Long MD, Woolcott JC, Wu J, McDonnell A, Goetsch M, Bananis E, Yarur AJ
doi: 10.1093/ibd/izaf036
COMMENTED
Inflammatory Bowel Disease
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Nutrients
Biedermann L, Doulberis M, Schreiner P, Nielsen OH, The FO, Brand S, Burk S, Hruz P, Juillerat P, Krieger-Grübel C, Leu K, Leventhal GE, Misselwitz B, Scharl S, Schoepfer A, Seibold F, Herfarth H, Rogler G
doi: 10.3390/nu16234197